Related references
Note: Only part of the references are listed.Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma
Jean-Sebastien Claveau et al.
BLOOD CANCER JOURNAL (2022)
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021
M. Hasib Sidiqi et al.
BLOOD CANCER JOURNAL (2021)
Comparison of Freelite and N-Latex serum free light chain assays: a critical review
Massimo Daves et al.
BIOCHEMIA MEDICA (2021)
Inter-assay variability in automated serum free light chain assays and their use in the clinical laboratory
Laura Caponi et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2020)
Method comparison of four clinically available assays for serum free light chain analysis
Cherina K. A. Fleming et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2020)
Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma
Aneta Schieferdecker et al.
BLOOD CANCER JOURNAL (2020)
Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients
Ben Sprangers et al.
KIDNEY INTERNATIONAL REPORTS (2020)
Different immunoreactivity of monomers and dimers makes automated free light chains assays not equivalent
Laura Caponi et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2019)
Response to article by Caponi et al. about serum free light chains
Jillian R. Tate et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2019)
Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease
Yang Yang et al.
HEALTH SCIENCE REPORTS (2019)
The use of serum free light chain dimerization patterns assist in the diagnosis of AL amyloidosis
Moshe E. Gatt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used
Xavier Bossuyt et al.
LEUKEMIA (2018)
Discrepancy between FLC assays: only a problem of quantification?
Laura Caponi et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: A pilot study
Batia Kaplan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
J. T. Larsen et al.
LEUKEMIA (2013)
Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease
E. Kastritis et al.
LEUKEMIA (2013)
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study
Benjamin M. Cherry et al.
LEUKEMIA & LYMPHOMA (2013)
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
Angela Dispenzieri et al.
BLOOD (2008)
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system
C. L. H. Snozek et al.
LEUKEMIA (2008)
Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma
Marie-Christine Kyrtsonis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Immunoglobulin free light chains and solitary plasmacytoma of bone
David Dingli et al.
BLOOD (2006)
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
SV Rajkumar et al.
BLOOD (2005)
Share Paper
